The prevalence of diabetes is increasing remarkably in Korea, reaching up to 10 percent of adult population. Diabetes increases the risk of cardiovascular event and also causes atherogenic dyslipidemia induced by insulin resistance (TG↑, small dense LDL↑, HDL ↓). The vascular disease is main cause of death in diabetes patient, so managing atherosclerosis is essentially needed. Although many studies suggest the importance of non-LDL-C levels in prevention of atherosclerosis in diabetes patients, lowering the LDL-C levels sufficiently is still in the center of intervention. Recent guidelines focus on the importance of lowering the LDL-C levels, but also on raising HDL-C and lowering TG levels in diabetes patients. The concept of “residual risk” is the recent focus of debate in the field of management of dyslipidemia in diabetes patients. In this talk, I will focus on recent statin trials related with lipid management in diabetes patients and also on the benefits of statin therapy in reduction of cardiovascular mortality in these populations, focusing the results in rosuvastatin trials.